Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Uterine Leiomyoma (Non Malignant Disorders) pipeline landscape.
Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uterine Leiomyoma (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 1, 2, 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Uterine Leiomyoma (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Non Malignant Disorders).
- The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uterine Leiomyoma (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uterine Leiomyoma (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Non Malignant Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Non Malignant Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) - Overview
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
AbbVie Inc
Bayer AG
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Endo International Plc
Eurofarma Laboratorios SA
Evestra Inc
GeneScience Pharmaceuticals Co Ltd
Immunitor Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Richter Gedeon Nyrt
TiumBio Co Ltd
Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
collagenase clostridium histolyticum - Drug Profile
Product Description
Mechanism Of Action
History of Events
CTX-30916 - Drug Profile
Product Description
Mechanism Of Action
Drug to Agonize Progesterone Receptor for Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
DWJ-1483 - Drug Profile
Product Description
Mechanism Of Action
EC-313 - Drug Profile
Product Description
Mechanism Of Action
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
goserelin acetate - Drug Profile
Product Description
Mechanism Of Action
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
linzagolix choline - Drug Profile
Product Description
Mechanism Of Action
History of Events
NCE-403 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHR-7280 - Drug Profile
Product Description
Mechanism Of Action
History of Events
triptorelin acetate ER - Drug Profile
Product Description
Mechanism Of Action
triptorelin acetate SR - Drug Profile
Product Description
Mechanism Of Action
ulipristal acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
V3-Myoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
vilaprisan - Drug Profile
Product Description
Mechanism Of Action
History of Events
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
Featured News & Press Releases
Feb 04, 2022: ObsEva provides update on EU marketing authorisation process for linzagolix, an oral GnRH antagonist, for the treatment of uterine fibroids
Dec 17, 2021: ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Nov 22, 2021: Obseva announces U.S. FDA acceptance of new drug application for Linzagolix
Oct 20, 2021: ObsEva presents clinical data on oral GnRH antagonist Linzagolix for the treatment of uterine fibroids at ASRM 2021 Scientific Congress & Expo
Oct 19, 2021: ObsEva announces presentation of clinical data on oral GnRH antagonist linzagolix at ASRM 2021 Scientific Congress & Expo
Sep 15, 2021: ObsEva announces submission of New Drug Application to U.S. FDA for Linzagolix for the treatment of Uterine Fibroids
Jun 30, 2021: ObsEva presents clinical data on open-label pilot study of Yselty (linzagolix) for the treatment of severe adenomyosis at ESHRE Virtual 37th Annual Meeting
Jun 24, 2021: ObsEva to present data on Yselty (linzagolix) at ESHRE Virtual 37th Annual Meeting
May 20, 2021: ObsEva announces final results from the phase 3 PRIMROSE program of Yselty (linzagolix) for the treatment of uterine fibroids
May 04, 2021: ObsEva announces enrollment completion of linzagolix phase 3 EDELWEISS 3 trial for patients with moderate to severe endometriosis-associated pain
Apr 30, 2021: ObsEva presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
Apr 27, 2021: ObsEva initiates PRIMROSE 3 bone mineral density follow-up study in PRIMROSE 1 and PRIMROSE 2 trial participants
Feb 18, 2021: Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Context Therapeutics Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Endo International Plc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Eurofarma Laboratorios SA, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Evestra Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Immunitor Inc, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Richter Gedeon Nyrt, 2022
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by TiumBio Co Ltd, 2022
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, 2022
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, 2022 (Contd..1)
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
